Adverum Biotechnologies Inc has a consensus price target of $25.86 based on the ratings of 7 analysts. The high is $60 issued by Truist Securities on May 15, 2024. The low is $2 issued by RBC Capital on March 19, 2024. The 3 most-recent analyst ratings were released by Chardan Capital, Oppenheimer, and Truist Securities on July 18, 2024, June 25, 2024, and May 15, 2024, respectively. With an average price target of $41.67 between Chardan Capital, Oppenheimer, and Truist Securities, there's an implied 414.40% upside for Adverum Biotechnologies Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/18/2024 | Buy Now | 393.83% | Chardan Capital | Daniil Gataulin | $4 → $40 | Maintains | Buy | Get Alert |
06/25/2024 | Buy Now | 208.64% | Oppenheimer | Francois Brisebois | → $25 | Initiates | → Outperform | Get Alert |
05/15/2024 | Buy Now | 640.74% | Truist Securities | Joon Lee | $60 → $60 | Maintains | Buy | Get Alert |
05/10/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Matthew Caufield | → $30 | Reiterates | Buy → Buy | Get Alert |
04/30/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Matthew Caufield | → $30 | Initiates | → Buy | Get Alert |
04/29/2024 | Buy Now | 171.6% | Mizuho | Graig Suvannavejh | $40 → $22 | Maintains | Buy | Get Alert |
03/19/2024 | Buy Now | -50.62% | Chardan Capital | Daniil Gataulin | → $40 | Reiterates | Buy → Buy | Get Alert |
03/19/2024 | Buy Now | -75.31% | RBC Capital | Luca Issi | $30 → $20 | Maintains | Sector Perform | Get Alert |
02/06/2024 | Buy Now | -50.62% | Mizuho | Graig Suvannavejh | $20 → $40 | Maintains | Buy | Get Alert |
11/02/2023 | Buy Now | -75.31% | Mizuho | Graig Suvannavejh | → $20 | Initiates | → Buy | Get Alert |
09/05/2023 | Buy Now | -25.93% | Truist Securities | Joon Lee | → $60 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | -50.62% | Chardan Capital | Daniil Gataulin | $20 → $40 | Upgrade | Neutral → Buy | Get Alert |
03/07/2023 | Buy Now | -75.31% | Ladenburg Thalmann | Aydin Huseynov | → $20 | Initiates | → Buy | Get Alert |
11/11/2022 | Buy Now | -75.31% | Chardan Capital | Daniil Gataulin | $25 → $20 | Maintains | Neutral | Get Alert |
11/11/2022 | Buy Now | -62.96% | RBC Capital | Luca Issi | $50 → $30 | Maintains | Sector Perform | Get Alert |
08/12/2022 | Buy Now | -69.14% | Chardan Capital | Daniil Gataulin | $30 → $25 | Maintains | Neutral | Get Alert |
07/07/2022 | Buy Now | -50.62% | Truist Securities | Joon Lee | $30 → $40 | Upgrade | Hold → Buy | Get Alert |
The latest price target for Adverum Biotechnologies (NASDAQ:ADVM) was reported by Chardan Capital on July 18, 2024. The analyst firm set a price target for $40.00 expecting ADVM to rise to within 12 months (a possible 393.83% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Adverum Biotechnologies (NASDAQ:ADVM) was provided by Chardan Capital, and Adverum Biotechnologies maintained their buy rating.
The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.
There is no last downgrade for Adverum Biotechnologies.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a maintained with a price target of $4.00 to $40.00. The current price Adverum Biotechnologies (ADVM) is trading at is $8.10, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.